Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?

Humby FC, Al Balushi F, Lliso G, Cauli A, Pitzalis C.

Front Med (Lausanne). 2017 May 3;4:41. doi: 10.3389/fmed.2017.00041. eCollection 2017. Review.

2.

Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.

Kiltz U, von Zabern C, Baraliakos X, Heldmann F, Mintrop B, Sarholz M, Krause D, Dybowski F, Kalthoff L, Braun J.

Arthritis Res Ther. 2017 Apr 7;19(1):73. doi: 10.1186/s13075-017-1279-z.

3.

Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review.

Beltrametti SP, Ianniello A, Ricci C.

Ther Clin Risk Manag. 2016 Nov 21;12:1763-1776. eCollection 2016. Review.

4.

Arthritis of the Knee Joint in Rheumatoid Arthritis - Evaluation of Treatment Response by Ultrasound in Daily Clinical Practice.

Schäfer VS, Schmidt WA, Backhaus M, Hartung W.

Open Rheumatol J. 2016 Oct 31;10:81-87. eCollection 2016.

5.

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis.

Lutt JR.

Open Access Rheumatol. 2009 May 8;1:17-35. eCollection 2009. Review.

6.

Early detection of spondyloarthropathy in patients with psoriasis by using the ultrasonography and magnetic resonance image.

Hamdy M, Omar G, Elshereef RR, Ellaban AS, Amin M.

Eur J Rheumatol. 2015 Mar;2(1):10-15. Epub 2015 Mar 1.

7.

Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.

Jansen JP, Vieira MC, Bradley JD, Cappelleri JC, Zwillich SH, Wallenstein GV.

BMC Musculoskelet Disord. 2016 Aug 18;17(1):348. doi: 10.1186/s12891-016-1195-4.

8.

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.

Li R, Zhao JX, Su Y, He J, Chen LN, Gu F, Zhao C, Deng XR, Zhou W, Hao YJ, Xue Y, Liu HX, Zhao Y, Zou QH, Liu XY, Zhu P, Sun LY, Zhang ZL, Zou HJ, Li XF, Liu Y, Fang YF, Keystone E, McInnes IB, Li ZG.

Medicine (Baltimore). 2016 Jul;95(28):e3968. doi: 10.1097/MD.0000000000003968.

9.

Therapeutic implications of autoantibodies in rheumatoid arthritis.

Aletaha D, Blüml S.

RMD Open. 2016 May 17;2(1):e000009. doi: 10.1136/rmdopen-2014-000009. eCollection 2016. Review.

10.

A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA).

Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EM, Emery P, Buch MH.

BMC Musculoskelet Disord. 2016 Feb 5;17:61. doi: 10.1186/s12891-016-0915-0.

11.

¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.

Priori R, Casadei L, Valerio M, Scrivo R, Valesini G, Manetti C.

PLoS One. 2015 Nov 11;10(11):e0138537. doi: 10.1371/journal.pone.0138537. eCollection 2015.

12.

The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects.

van der Goes MC, Jacobs JW, Bijlsma JW.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S2. doi: 10.1186/ar4686. Review.

13.

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.

Cutolo M, Spies CM, Buttgereit F, Paolino S, Pizzorni C.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S1. doi: 10.1186/ar4685. Review.

14.

Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Yamashita H, Kubota K, Mimori A.

Arthritis Res Ther. 2014;16(5):423. Review.

15.

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH.

J Clin Endocrinol Metab. 2015 Feb;100(2):363-70. doi: 10.1210/jc.2014-3421. Epub 2015 Jan 15. Review.

16.

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

Peterfy C, Emery P, Tak PP, Østergaard M, DiCarlo J, Otsa K, Navarro Sarabia F, Pavelka K, Bagnard MA, Gylvin LH, Bernasconi C, Gabriele A.

Ann Rheum Dis. 2016 Jan;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015. Epub 2014 Oct 29.

17.

Dashboard systems: implementing pharmacometrics from bench to bedside.

Mould DR, Upton RN, Wojciechowski J.

AAPS J. 2014 Sep;16(5):925-37. doi: 10.1208/s12248-014-9632-5. Epub 2014 Jun 20. Review.

18.

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.

Kavanaugh A, Wells AF.

Rheumatology (Oxford). 2014 Oct;53(10):1742-51. doi: 10.1093/rheumatology/keu135. Epub 2014 Apr 10. Review.

19.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

20.

Pharmacotherapy options in rheumatoid arthritis.

Kumar P, Banik S.

Clin Med Insights Arthritis Musculoskelet Disord. 2013 Aug 8;6:35-43. doi: 10.4137/CMAMD.S5558. eCollection 2013.

Supplemental Content

Support Center